Suggested remit: To appraise the clinical and cost effectiveness of quizartinib within its marketing authorisation as an induction, consolidation and maintenance therapy for treating newly diagnosed FLT3-ITD-positive acute myeloid leukaemia.
 
Status In progress
Technology type Medicine
Decision Selected
Process STA Standard
ID number 4042

Provisional Schedule

Committee meeting 06 August 2024
Expected publication 16 October 2024

Project Team

Project lead Louise Jafferally

Email enquiries

External Assessment Group Centre for Reviews and Dissemination and Centre for Health Economics, University of York

Stakeholders

Companies sponsors Daiichi Sankyo UK (quizartinib)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Blood Cancer UK
  Leukaemia Care
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
Associated public health groups None
Comparator companies Jazz Pharmaceuticals (cytarabine, daunorubicin) (confidentiality agreement returned, participating)
  Novartis Pharmaceuticals (midostaurin) (confidentiality agreement returned, participating)
  Accord Healthcare (cytarabine,
  mitoxantrone) (confidentiality agreement not returned, not participating)
  Baxter Healthcare (mitoxantrone) (confidentiality agreement not returned, not participating)
  Celgene (azacitidine) (confidentiality agreement not returned, not participating)
  Eurocept International (amsacrine) (confidentiality agreement not returned, not participating)
  Hospira UK (cytarabine) (confidentiality agreement not returned, not participating)
  Medac (etoposide) (confidentiality agreement not returned, not participating)
  Napp Pharmaceuticals (cytarabine) (confidentiality agreement not returned, not participating)
  Neon Healthcare (etoposide) (confidentiality agreement not returned, not participating)
  Pfizer (cytarabine) (confidentiality agreement not returned, not participating)
  Zentiva UK (daunorubicin) (confidentiality agreement not returned, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
26 September 2023 Invitation to participate
20 July 2023 - 17 August 2023 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 4042
20 July 2023 In progress. Scoping commencing
05 January 2023 Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin in late August 2023 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately early November 2023.

For further information on our processes and methods, please see our CHTE processes and methods manual